NO810024L - Fremgangsmaate for fremstilling av farmasoeytisk aktive pyrimidinonderivater. - Google Patents

Fremgangsmaate for fremstilling av farmasoeytisk aktive pyrimidinonderivater.

Info

Publication number
NO810024L
NO810024L NO810024A NO810024A NO810024L NO 810024 L NO810024 L NO 810024L NO 810024 A NO810024 A NO 810024A NO 810024 A NO810024 A NO 810024A NO 810024 L NO810024 L NO 810024L
Authority
NO
Norway
Prior art keywords
group
het
alk
formula
ring
Prior art date
Application number
NO810024A
Other languages
English (en)
Norwegian (no)
Inventor
Mikkel Josef Gacek
Kjell Undheim
Original Assignee
Nyegaard & Co As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nyegaard & Co As filed Critical Nyegaard & Co As
Publication of NO810024L publication Critical patent/NO810024L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30Halogen atoms or nitro radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/42Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28Halogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
NO810024A 1980-01-07 1981-01-06 Fremgangsmaate for fremstilling av farmasoeytisk aktive pyrimidinonderivater. NO810024L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8000381 1980-01-07

Publications (1)

Publication Number Publication Date
NO810024L true NO810024L (no) 1981-07-08

Family

ID=10510470

Family Applications (1)

Application Number Title Priority Date Filing Date
NO810024A NO810024L (no) 1980-01-07 1981-01-06 Fremgangsmaate for fremstilling av farmasoeytisk aktive pyrimidinonderivater.

Country Status (13)

Country Link
US (1) US4399140A (de)
EP (1) EP0032131B1 (de)
JP (1) JPS56150087A (de)
AT (1) ATE4715T1 (de)
AU (1) AU543939B2 (de)
CA (1) CA1168239A (de)
DE (1) DE3160886D1 (de)
DK (1) DK149892B (de)
ES (2) ES498337A0 (de)
IE (1) IE50765B1 (de)
NO (1) NO810024L (de)
NZ (1) NZ195947A (de)
ZA (1) ZA8164B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ197715A (en) * 1980-07-15 1984-12-14 Glaxo Group Ltd Substituted pyrimin-2-ones and pharmaceutical compositions
NZ197714A (en) * 1980-07-15 1984-11-09 Glaxo Group Ltd Substituted pyrimidin-2-ones and pharmaceutical compositions
DE3270525D1 (en) * 1981-01-09 1986-05-22 Nyegaard & Co As Substituted pyrimidin-2-ones and the salts thereof
AU1179883A (en) * 1982-02-24 1983-09-01 Nyegaard & Co. A/S Pyrimidin-z-ones
SU1235864A1 (ru) * 1983-03-11 1986-06-07 Отделение ордена Ленина института химической физики АН СССР Нитроксильные производные 5-фторурацила,обладающие противоопухолевой активностью
CN103130732A (zh) * 2011-11-22 2013-06-05 上海博康精细化工有限公司 3,5-二甲基-4-氯甲基异噁唑的制备方法
CN107074805B (zh) 2014-07-03 2021-02-26 德州大学系统董事会 用于治疗疾病的gls1抑制剂
WO2016004417A1 (en) * 2014-07-03 2016-01-07 Board Of Regents, University Of Texas System Gls1 inhibitors for treating disease
EP3316887B1 (de) 2015-06-30 2020-04-08 Board of Regents, The University of Texas System Gls1-hemmer zu behandlung von erkrankungen
BR112018012660B1 (pt) 2015-12-22 2023-12-19 Board Of Regents, The University Of Texas System Sal, solvato, ou polimorfo de um composto; polimorfo de composto sólido; composição; e uso de um sal, solvato ou polimorfo
US10722487B2 (en) 2017-10-18 2020-07-28 Board Of Regents, The University Of Texas System Glutaminase inhibitor therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3833586A (en) * 1971-03-25 1974-09-03 Morton Norwich Products Inc 1-(substituted benzyl)-2-(1h)pyrimidones and 1-(substituted benzyl)tetrahydro-2-(1h)pyrimidones
GB1561290A (en) * 1975-10-16 1980-02-20 Nyegaard & Co As Pyrimid - 2 - ones
US4003900A (en) * 1976-03-11 1977-01-18 Morton-Norwich Products, Inc. 1-Benzyl-5-chloro-2-(1H)-pyrimidone
US4052399A (en) * 1976-09-13 1977-10-04 Morton-Norwich Products, Inc. 1-[2-(Hexahydro-1H-azepino)ethyl]-2(1H)pyrimidone dihydrochloride
US4052400A (en) * 1976-10-29 1977-10-04 Morton-Norwich Products, Inc. Hypertensive 1-substituted 2(1h)-pyrimidones

Also Published As

Publication number Publication date
IE50765B1 (en) 1986-07-09
DE3160886D1 (en) 1983-10-27
DK3281A (da) 1981-07-08
EP0032131B1 (de) 1983-09-21
ES509219A0 (es) 1983-03-16
CA1168239A (en) 1984-05-29
AU543939B2 (en) 1985-05-09
EP0032131A1 (de) 1981-07-15
ES8304946A1 (es) 1983-03-16
US4399140A (en) 1983-08-16
NZ195947A (en) 1983-09-02
ES8205399A1 (es) 1982-06-01
ATE4715T1 (de) 1983-10-15
JPS56150087A (en) 1981-11-20
IE810013L (en) 1981-07-07
ZA8164B (en) 1982-03-31
AU6601681A (en) 1981-07-16
ES498337A0 (es) 1982-06-01
DK149892B (da) 1986-10-20

Similar Documents

Publication Publication Date Title
AU2004228352B2 (en) Aminopyrimidine derivatives and their medical use
JP5624762B2 (ja) 新規ピロリノン誘導体およびそれを含有する医薬組成物
ES2240449T3 (es) Moduladores receptores de adenosina.
EP1675861B1 (de) Pyrimidothiophenverbindungen
CN110028491B (zh) 纤维母细胞生长因子受体抑制剂
CN105143206B (zh) 用于治疗癌症的嘧啶-2,4-二胺衍生物
CA2589328A1 (en) Multicyclic bis-amide mmp inhibitors
US20120309739A1 (en) Akt / pkb inhibitors
AU2004215428A1 (en) Aminoheteroaryl compounds as protein kinase inhibitors
AU2008252380A1 (en) Quinazolin-oxime derivatives as Hsp90 inhibitors
KR20130122778A (ko) FAK/Pyk2 억제제인 2,4-디아미노-6,7-디히드로-5H-피롤로[2,3]피리미딘 유도체
NO810024L (no) Fremgangsmaate for fremstilling av farmasoeytisk aktive pyrimidinonderivater.
El‐Mekabaty et al. Convenient synthesis of novel sulfonamide derivatives as promising anticancer agents
BR112019024376A2 (pt) composto de fórmula geral (i), ou sais farmaceuticamente aceitáveis destes, composição farmacêutica e uso dos compostos ou sais farmaceuticamente aceitáveis destes
IE83508B1 (en) Quinoxalines, processes for their preparation, and their use
CN115702150A (zh) Cd73抑制剂及其在医药上的应用
US3463850A (en) Arabinofuranosyl 2-thiopyrimidines and pharmaceutical compositions thereof
AU2021410926A9 (en) Tetrahydrothienopyrimidinesulfonamide compounds
Strekowski et al. Synthesis of 2‐chloro‐4, 6‐di (heteroaryl) pyrimidines
Li et al. Synthesis and Bioevaluation of Thieno [2, 3‐d] pyrimidinone Derivatives as Potential Tumor Cell Growth Inhibitors
AU2007334039B2 (en) Imidazolidinonyl aminopyrimidine compounds for the treatment' of cancer
KR20090086111A (ko) 암의 치료를 위한 이미다졸리디노닐 아미노피리미딘 화합물
TWI676625B (zh) 磺醯胺類衍生物、其製備方法及其在醫藥上的用途
NO135421B (de)
US4650800A (en) Substituted pyrimidin-2-ones, the salts thereof, pharmaceutical compositions containing them and a method therefor